Keyphrases
Adult T-cell Leukemia
67%
Integrin
66%
Tumor Growth
64%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
58%
Breast Cancer
56%
Bone Loss
54%
Tumor
52%
Granulocyte Colony-stimulating Factor (G-CSF)
50%
Multiple Myeloma
43%
Myeloma Cells
43%
Targeted Therapy
43%
Viral Oncogenes
43%
Bone Metastasis
42%
Macrophages
42%
Mouse Model
40%
Pathologic
32%
Triple-negative Breast Cancer
32%
Nanotherapeutics
29%
Bone Tumor
29%
Tumor Cells
29%
Jurkat
29%
Allogeneic Donors
29%
Scoring Model
29%
T-cell Malignancies
28%
Chemotherapy-induced
27%
Parathyroid Hormone-related Protein (PTHrP)
26%
Metastatic Breast Cancer
24%
Human Mesenchymal Stem Cells (hMSCs)
24%
Hematopoietic Stem Cells
24%
Pro-tumor
24%
Human Adult
24%
Tumoral
24%
Metastasis
24%
Myeloid Cells
23%
Tumor-associated Macrophages
23%
Bortezomib Resistance
21%
Breast Cancer Bone Metastasis
21%
Cytokine Release Syndrome
21%
Molecular Targets
21%
Universal CAR-T
21%
Transferrin Receptor 1 (TfR1)
21%
Primary Breast Cancer
21%
Antitumor
21%
Immunosuppression
21%
CXCR4 Protein
21%
Chemoresistance
21%
Acetate Metabolism
21%
Tumor Growth in Vivo
21%
COVID-19
21%
Non-competitive
21%
Medicine and Dentistry
Neoplasm
100%
Tumor Progression
80%
Adult T-Cell Leukemia/Lymphoma
77%
Breast Cancer
66%
Osteolysis
55%
Human T-Lymphotropic Virus 1
52%
Integrin
47%
Metastatic Carcinoma
45%
Bone Metastasis
44%
Multiple Myeloma
43%
Virus Oncogene
43%
HBZ
43%
Bone Cancer
38%
Tumor Cell
35%
Macrophage
32%
Malignant Neoplasm
31%
In Vitro
29%
Triple Negative Breast Cancer
29%
Nanoparticle
25%
Metastatic Breast Cancer
24%
Targeted Therapy
24%
Immunosuppressive Treatment
24%
Tumor Microenvironment
24%
Myeloid Cell
23%
Bone Disease
22%
Granulocyte Macrophage Colony Stimulating Factor
21%
Drug Resistance
21%
Cancer Staging
21%
Immunosuppressive Drug
21%
Transferrin Receptor
21%
Nerve Cell Adhesion Molecule
21%
Imidazoline
21%
Arginase 1
21%
Epitope
21%
Solid Malignant Neoplasm
21%
Parathyroid Hormone-Related Protein
21%
Drive
21%
COVID-19
21%
Bone Destruction
21%
Acetic Acid
21%
Heparanase
21%
Bortezomib
21%
Proteasome
21%
Myeloproliferative Neoplasm
21%
Hematopoietic Stem Cell
21%
Prodrug
21%
Zoledronic Acid
21%
Hedgehog Signaling
21%
Tumor Model
21%
Tumor Suppressor Protein
21%